Business Insights, VIEWS AND ANALYSIS

A Brief Synopsis of Modern Randomization Methodologies and Technologies

December 9, 2022

A Brief Synopsis
Randomized, double-blind clinical trials are the gold standard for adequate and well-controlled studies in modern
times. However, prior to the late 1940s, randomization and blinding were not used in medicine and as result,
bias was common.

Spotlight

Mangalam Drugs & Organics Ltd

Mangalam Drugs & Organics Limitedcommenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and Intermediates at VAPI – Gujarat in 1977. It has a multi product manufacturing facility on two locations, and an in-house R&D laboratory. Over the last three decades Mangalam has acquired worldwide reputation as a single stop destination for frontline Anti malarials.

OTHER WHITEPAPERS
news image

The Next Generation of Rare Disease Drug Policy

whitePaper | April 7, 2022

The United States defines a rare disease as a condition affecting fewer than 200,000 people in the country or one in which “there is no reasonable expectation” of recovering research and development costs.1 Examples of rare diseases include genetically-linked cancers, cystic fibrosis, and debilitating pediatric conditions like Gaucher disease and spinal muscular atrophy

Read More
news image

Coronavirus (COVID-19) and Its Effect on Pharmaceutical Marketing and Sales

whitePaper | March 16, 2020

With the rapid onset of coronavirus in the United States, many pharma companies are being forced to prepare for a scenario in which their reps cannot visit providers and patients are limited in their ability to visit their healthcare professionals (HCP). The CDC has gone as far as recommending the use of telemedicine and patient portals as primary channels for HCPs and patients to interact.

Read More
news image

How Specialty Pharmacy Can Drive Better Outcomesin Multiple Sclerosis

whitePaper | June 14, 2022

Multiple sclerosis (MS) is a chronic, inflammatory disease of the central nervous system. Characterized by demyelination and neurodegeneration that affects the communication between the brain and other parts of the body, MS leads to physical and cognitive disability.

Read More
news image

New Active Substances Launched During 2021

whitePaper | June 27, 2022

Following on from our review of trends in the current pharmaceutical R&D pipeline this supplement takes a look at the industry’s success stories of 2021

Read More
news image

Learning from the COVID-19 Policy Response

whitePaper | November 3, 2022

This document is published by the World Economic Forum as a contribution to a project, insight area or interaction. The findings, interpretations and conclusions expressed herein are a result of a collaborative process facilitated and endorsed by the World Economic.

Read More
news image

Streamlining Distribution in the Pharmaceutical Industry

whitePaper | November 25, 2022

Satyendra Sinha is a Functional Consultant with the TCS Life Sciences unit, and focuses on order management, distribution.

Read More

Spotlight

Mangalam Drugs & Organics Ltd

Mangalam Drugs & Organics Limitedcommenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and Intermediates at VAPI – Gujarat in 1977. It has a multi product manufacturing facility on two locations, and an in-house R&D laboratory. Over the last three decades Mangalam has acquired worldwide reputation as a single stop destination for frontline Anti malarials.

Events